HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $5 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Patrick Trucchio has reiterated a 'Buy' rating on Sangamo Therapeutics (NASDAQ:SGMO) and maintained a $5 price target.
August 14, 2023 | 10:17 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sangamo Therapeutics has been reiterated with a 'Buy' rating by HC Wainwright & Co. The price target remains at $5.
The 'Buy' rating from HC Wainwright & Co. indicates a positive outlook for Sangamo Therapeutics. The maintained price target of $5 suggests that the analyst believes the stock is undervalued at current levels, which could lead to upward price movement in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100